Karaskova E, Volejnikova J, Holub D, et al. - In this longitudinal study, researchers contrasted changes in serum hepcidin levels in paediatric patients with inflammatory bowel disease during therapy and correlate them with markers of iron metabolism, inflammation and type of treatment. In order to evaluate levels of serum hepcidin and markers of iron metabolism parameters and inflammation, blood and stool samples were collected. According to results, patients with CD (n = 30) had higher serum hepcidin levels (expressed as a median and interquartile range) at diagnosis compared with patients with UC (n = 13). Compared with patients with UC, those with CD had higher serum hepcidin levels on the diagnosis. Serum hepcidin reduced in the CD group but remained consistently low in children with UC during an anti-inflammatory therapy.